Tirzepatide and Constipation: Causes, Management, and When to Seek Help

Nausea tends to dominate conversations about tirzepatide side effects. Constipation deserves equal attention. It affects roughly one in four people who start tirzepatide, and unlike nausea, it does not reliably resolve on its own within the first few weeks.

The good news: constipation on tirzepatide is manageable for most people with the right combination of dietary changes, hydration, and consistent habits. This guide covers why it happens, what the clinical trial data actually shows about how common it is, practical strategies that work, and the specific signs that mean it is time to contact your provider.

*Compounded tirzepatide is not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Individual results vary. Always consult your licensed healthcare provider before starting or adjusting any medication.*

---

Why Tirzepatide Causes Constipation

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Unlike semaglutide, which activates only the GLP-1 receptor, tirzepatide simultaneously activates two hormone receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both of these receptors play a role in gastrointestinal function, and activating them produces meaningful effects throughout the digestive tract.

GLP-1 receptors are distributed widely across the gut, and when activated, they slow the rate at which food moves through the digestive system. This gastric emptying delay is the intended therapeutic effect: slower stomach emptying extends satiety and reduces appetite. But that slowing extends beyond the stomach into the small and large intestine as well. As contents move more slowly through the colon, more water is absorbed from them. The result is stool that is drier, harder, and more difficult to pass.

GIP receptors also appear to contribute to reduced gut motility, though the precise mechanisms are still being studied. Research in *Neurogastroenterology and Motility* has documented that GLP-1 receptor activity in the enteric nervous system, the nerve network lining the gut, directly reduces colonic contraction frequency beyond the gastric emptying effect alone (Tack J et al., 2012; PMID: 22309540). Tirzepatide's dual mechanism means both receptors are working simultaneously on this system.

The result: tirzepatide slows digestion at multiple points. For a meaningful subset of users, that translates into constipation, particularly at higher doses where the effect is stronger.

---

What the Clinical Trials Show

The SURMOUNT-1 trial, published in the *New England Journal of Medicine* in 2022, is the most comprehensive source of constipation data for tirzepatide. The trial enrolled 2,539 adults with obesity, randomizing them to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks. (SURMOUNT-1 studied FDA-approved branded tirzepatide formulations; compounded tirzepatide is a separate, non-FDA-approved formulation, and constipation rates for compounded versions have not been established in controlled trials.)

Constipation rates showed a clear dose-dependent pattern. At the 5 mg dose, approximately 17.3 percent of participants reported constipation, compared to 21.6 percent at 10 mg and 24.5 percent at 15 mg. The placebo group reported a rate of approximately 8.9 percent. Constipation was among the most frequently reported gastrointestinal adverse events alongside nausea, vomiting, and diarrhea (Jastreboff AM et al., 2022; PMID: 35658024).

This dose-response relationship is clinically meaningful. It suggests that the 5 mg starting dose is lower risk for constipation than the maintenance doses, but that as titration progresses toward 10 mg and 15 mg, constipation risk increases. Many people who tolerate the initial doses without digestive issues develop constipation as their dose increases.

SURMOUNT-2, which enrolled adults with type 2 diabetes alongside obesity, found a similar pattern. Gastrointestinal adverse events were among the most common side effects across the tirzepatide arms, with constipation present throughout the treatment period rather than resolved after an initial adjustment phase (Garvey WT et al., 2023; PMID: 37385275).

SURPASS-2, a head-to-head trial comparing tirzepatide to semaglutide 1 mg (a dose lower than the 2.4 mg weight-loss dose), found broadly similar gastrointestinal side effect profiles between the two medications at equivalent therapeutic stages (Frías JP et al., 2021; PMID: 34170647). The key takeaway: constipation is a class-wide GLP-1 effect, and tirzepatide's higher-dose constipation rates reflect both its potency and its dual receptor mechanism.

---

The Reduced-Appetite Compounding Effect

There is a dynamic with tirzepatide constipation worth understanding separately from the pharmacology. When appetite is substantially reduced, total food intake drops significantly. Less food volume means less material moving through the digestive tract. That lower bulk, combined with tirzepatide's slowing of gut motility, creates a layered effect that is harder to reverse than either factor alone.

Reduced fiber intake is the most important downstream consequence. If you were previously getting adequate fiber from a larger volume of food and are now eating much less, your fiber intake may have dropped substantially without you noticing. Fiber is the primary driver of stool bulk and water retention in the colon. When intake falls, constipation follows.

This dynamic also explains why constipation on tirzepatide can worsen as the medication becomes more effective at suppressing appetite. At 5 mg, appetite suppression is moderate. At 15 mg, it is pronounced. The better the medication works at reducing how much you eat, the more intentional you need to be about maintaining adequate fiber and fluid intake within a smaller eating volume.

---

*Dietary fiber is the single most effective intervention for tirzepatide-related constipation. Aim for 25 to 38 grams per day from whole food sources.*

---

6 Strategies That Help Most People

These approaches work with the physiology of how tirzepatide affects gut motility. They are not complicated, but they require consistency over several weeks to produce reliable improvement.

1. Increase Fiber Intake, Gradually

Dietary fiber is the foundation of constipation management on tirzepatide. Soluble fiber, found in oats, lentils, beans, apples, and psyllium husk, absorbs water and forms a gel that softens stool. Insoluble fiber, found in whole grains, wheat bran, and most vegetables, adds bulk and helps move material through the colon.

The target for adults is 25 to 38 grams of fiber daily, depending on sex and body weight, according to guidelines from the American College of Gastroenterology (Ford AC et al., 2014; PMID: 24813350). Most people eating at a tirzepatide-suppressed appetite fall significantly short of that.

Increase fiber gradually rather than all at once. Adding too much too quickly causes bloating, gas, and cramping. A practical approach is to add roughly 5 grams per week until you reach an adequate intake. Psyllium husk powder, such as plain unflavored Metamucil or a generic equivalent, is one of the most effective ways to add soluble fiber when food volume is reduced.

2. Drink More Water Than You Think You Need

Fiber without adequate hydration makes constipation worse. Fiber works by absorbing water in the colon. If your fluid intake is insufficient, added fiber simply becomes denser, harder-to-pass stool rather than a softening agent.

A target of 8 to 10 cups (64 to 80 oz) of water daily is a reasonable baseline for most adults. On tirzepatide, the same appetite suppression that reduces food intake also blunts the drive to drink. Consistent, deliberate hydration throughout the day matters more than relying on thirst as a signal.

Plain water is the most effective hydration source. Caffeinated beverages have a mild diuretic effect and are a less efficient fluid source than water, though moderate coffee intake is not a significant concern for most people.

3. Move Your Body Daily

Physical activity stimulates peristalsis, the muscular contractions that propel stool through the colon. Even modest regular movement, such as a 20 to 30 minute walk, has been shown in clinical populations to meaningfully reduce constipation frequency and severity (de Oliveira EP & Burini RC, 2009; PMID: 19568184).

This is relevant for people on tirzepatide because reduced-calorie intake can reduce energy levels, making sedentary periods more common. Light daily movement, even when energy is low, provides meaningful digestive benefit and compounds over time.

4. Build Consistent Bathroom Habits

The gastrocolic reflex is a normal increase in colonic activity that follows eating, particularly the first meal of the day. This is the body's natural prompt for bowel movements. On tirzepatide, reduced food intake produces a weaker gastrocolic reflex signal. You can work with this by making time after your first meal a consistent opportunity for a bowel movement, even when the urge is not strong.

Sitting on the toilet for 5 to 10 minutes after a morning meal, without pressure or urgency, allows the reflex to do its work. Over time, this routine trains a more regular pattern. Squatting-position toilet stools, which slightly elevate the feet to better align the colon, have evidence supporting their use for reducing straining and improving evacuation completeness (Sikirov D, 2003; PMID: 12839282).

5. Consider Osmotic Laxatives for Short-Term Relief

When dietary changes are not providing adequate relief, osmotic laxatives are a safe, well-evidenced option for short-term use. These draw water into the colon to soften stool without stimulating muscular contractions.

Polyethylene glycol (PEG), sold as Miralax, is among the most studied and well-tolerated options. It is non-habit-forming, typically works within one to three days, and is widely recommended in gastroenterology guidelines for functional constipation (Ford AC et al., 2014; PMID: 24813350). Magnesium citrate and magnesium oxide are alternatives in the same osmotic category.

Stimulant laxatives such as senna or bisacodyl act by directly triggering colon contractions. They provide faster relief but carry a higher risk of cramping and are not appropriate for regular use. If you need short-term relief beyond what dietary changes provide, start with an osmotic option.

Discuss any new supplements or laxative use with your provider before starting, particularly if you have kidney disease, heart conditions, or are taking other medications.

6. Prioritize Fiber-Rich Foods Within a Smaller Eating Volume

The reduced appetite from tirzepatide means the specific composition of what you eat has more impact on digestive health than when you were eating larger volumes. Prioritizing high-fiber choices within a smaller eating pattern is the goal.

Foods that deliver meaningful fiber in small portions: cooked lentils, chickpeas, and black beans; raspberries and blackberries; cooked artichokes; split peas; avocado; and oatmeal. These are practical options when eating volume is low. For a more complete guide to eating patterns during tirzepatide treatment, see the guide on [what to eat on tirzepatide](/resources/what-to-eat-on-tirzepatide).

---

Foods That Often Make It Worse

Certain foods that are easy to lean on when appetite is low tend to worsen constipation. Low-fiber, processed foods are the primary category.

Reduce or avoid:

• White bread, white rice, and refined grain products (low fiber, slow transit)
• Processed snacks, crackers, and chips (low fiber, often dehydrating due to sodium)
• Red meat in large quantities (low fiber, slower to digest)
• Dairy products in excess (can contribute to constipation in some individuals)
• Alcohol (dehydrating and can worsen constipation; see the guide on [tirzepatide and alcohol](/resources/tirzepatide-and-alcohol))

This is not about eliminating these foods entirely. It is about recognizing that when total food intake is reduced, the composition of what you eat has an outsized effect on how well your digestive system functions.

---

When to Seek Help

Most constipation on tirzepatide responds to consistent dietary management within one to two weeks. There are specific situations where constipation warrants prompt contact with your provider rather than continued home management.

Contact your provider if:

• You have not had a bowel movement in more than four to five days, especially if accompanied by abdominal discomfort, bloating, or nausea. Prolonged constipation can lead to fecal impaction, a condition where hardened stool cannot pass without medical intervention.

• You experience severe or worsening abdominal pain. Sharp, cramping, or unusually intense abdominal pain that differs from ordinary constipation discomfort may indicate a more serious issue, including possible intestinal obstruction. While rare, GLP-1 receptor agonists have been associated with ileus in post-marketing safety reports. This warrants evaluation rather than home management.

• You notice blood in your stool or significant rectal bleeding. Small amounts of bright red blood after straining may result from hemorrhoids or minor anal fissures, both more common when constipation causes excessive straining. However, blood in stool always warrants a provider evaluation to rule out other causes.

• Constipation is accompanied by vomiting, inability to pass gas, or significant abdominal distension. This combination may indicate bowel obstruction and requires prompt medical attention.

• Constipation persists despite four to six weeks of consistent dietary changes, adequate hydration, and over-the-counter osmotic laxative use. Your provider may consider adjusting your dose, slowing your titration schedule, or investigating whether another cause is contributing.

• You are taking other medications that can worsen constipation, including opioids, iron supplements, calcium channel blockers, or certain antidepressants. The combination of these with tirzepatide's gut-slowing effects can be additive and may require coordinated management.

Do not stop tirzepatide without talking to your provider first. Constipation is manageable and is rarely a reason to discontinue treatment on its own. Your provider can help you find the right approach, whether that involves a dose adjustment, a slower titration schedule, or a specific supportive intervention.

---

The Bottom Line

Constipation affects roughly one in four people on tirzepatide, with rates rising as doses increase toward the 10 mg and 15 mg maintenance levels. Unlike nausea, which tends to resolve as the body adapts, constipation often persists throughout treatment and requires active management.

The strategies here, consistent fiber intake, adequate hydration, daily movement, and thoughtful food choices, work with the physiology of how tirzepatide affects the gut. They take a few weeks of sustained effort to show full results. Starting early in treatment, before constipation becomes entrenched, produces better outcomes than waiting until it is already severe.

If constipation is not improving with home management, if it is severe, or if you experience red flag symptoms such as blood in stool, inability to pass gas, or significant abdominal pain, contact your provider. These are situations where clinical guidance and possibly intervention are the right next step.

---

Sources

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med.* 2022;387(3):205-216. [PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)

1. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet.* 2023;402(10402):613-626. [PMID: 37385275](https://pubmed.ncbi.nlm.nih.gov/37385275/)

1. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *N Engl J Med.* 2021;385(6):503-515. [PMID: 34170647](https://pubmed.ncbi.nlm.nih.gov/34170647/)

1. Tack J, et al. Gastrointestinal mechanisms underpinning the side effects of glucagon-like peptide-1 receptor agonists. *Neurogastroenterology and Motility.* 2012;24(12):1082-1091. [PMID: 22309540](https://pubmed.ncbi.nlm.nih.gov/22309540/)

1. Ford AC, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *American Journal of Gastroenterology.* 2014;109 Suppl 1:S2-26. [PMID: 24813350](https://pubmed.ncbi.nlm.nih.gov/24813350/)

1. de Oliveira EP, Burini RC. The impact of physical exercise on the gastrointestinal tract. *Current Opinion in Clinical Nutrition and Metabolic Care.* 2009;12(5):533-538. [PMID: 19568184](https://pubmed.ncbi.nlm.nih.gov/19568184/)

1. Sikirov D. Comparison of straining during defecation in three positions: results and implications for human health. *Digestive Diseases and Sciences.* 2003;48(7):1201-1205. [PMID: 12839282](https://pubmed.ncbi.nlm.nih.gov/12839282/)

---

Compounding Disclaimer: Compounded tirzepatide is not an FDA-approved medication. It has not been reviewed by the FDA for safety, efficacy, or quality. Compounded tirzepatide is not the same as, not equivalent to, and should not be considered interchangeable with Mounjaro or Zepbound.

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.